Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease

Current Topics in Medicinal Chemistry

Volumn 13, Issue 11, 2013, Pages 1353-1362

  Reid, Terry Elinor ^a   Kumar, Krishna ^a   Wang, Xiang Simon ^a  

^a HOWARD UNIVERSITY   (United States)

Author keywords

5 hydroxytryptamine (serotonin) receptor 2B; Cheminformatics; G protein coupled receptors; Homology modeling; In silico; Molecular docking; Molecular dynamics; Quantitative structure activity relationship; Valvular heart disease; Virtual screening

Indexed keywords

3, 4 METHYLENEDIOXYMETHAMPHETAMINE; AGOMELATINE; AMPHETAMINE; ASENAPINE; CABERGOLINE; ERGOT ALKALOID; ERGOTAMINE; FENFLURAMINE; G PROTEIN COUPLED RECEPTOR; KETANSERIN; LYSERGIDE; METHYLERGOMETRINE; METHYSERGIDE; NORFENFLURAMINE; PERGOLIDE; RITANSERIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1E RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 2B RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG; YOHIMBINE;

COMPUTER MODEL; DRUG CLASSIFICATION; DRUG SCREENING; HUMAN; NONHUMAN; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TOXICITY; VALVULAR HEART DISEASE;

COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HEART VALVE DISEASES; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 84881347056     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990039     Document Type: Review

References (52)

1. Filmore, D. It's a GPCR world. Modern Drug Discovery, 2004, 7 (11), 24-28.
2. Brea, J.; Castro-Palomino, J.; Yeste, S.; Cubero, E.; Parraga, A.; Dominguez, E.; Loza, M. I. Emerging opportunities and concerns for drug discovery at serotonin 5-HT2B receptors. Curr. Top. Med. Chem., 2010, 10 (5), 493-503.
3. Pytliak, M.; Vargova, V.; Mechirova, V.; Felsoci, M. Serotonin receptors-from molecular biology to clinical applications. Physiol Res., 2011, 60 (1), 15-25.
4. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 1994, 46 (2), 157-203.
5. Nichols, D. E.; Nichols, C. D. Serotonin receptors. Chem. Rev., 2008, 108 (5), 1614-1641.
6. Bonhaus, D. W.; Bach, C.; DeSouza, A.; Salazar, F. H.; Matsuoka, B. D.; Zuppan, P.; Chan, H. W.; Eglen, R. M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol., 1995, 115 (4), 622-628.
7. Choi, D. S.; Birraux, G.; Launay, J. M.; Maroteaux, L. The human serotonin 5-HT2B receptor: pharmacological link between 5-HT2 and 5-HT1D receptors. FEBS Lett., 1994, 352 (3), 393-399.
8. Choi, D. S.; Maroteaux, L. Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett., 1996, 391 (1-2), 45-51.
9. Duxon, M. S.; Flanigan, T. P.; Reavley, A. C.; Baxter, G. S.; Blackburn, T. P.; Fone, K. C. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience, 1997, 76 (2), 323-329.
10. Smith, S. A.; Waggoner, A. D.; de las, F. L.; Davila-Roman, V. G. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J. Am. Soc. Echocardiogr., 2009, 22 (8), 883-889.
11. Doly, S.; Valjent, E.; Setola, V.; Callebert, J.; Herve, D.; Launay, J. M.; Maroteaux, L. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neurosci., 2008, 28 (11), 2933-2940.
12. Wouters, M. M.; Gibbons, S. J.; Roeder, J. L.; Distad, M.; Ou, Y.; Strege, P. R.; Szurszewski, J. H.; Farrugia, G. Exogenous serotonin regulates proliferation of interstitial cells of Cajal in mouse jejunum through 5-HT2B receptors. Gastroenterology, 2007, 133 (3), 897-906.
13. Sanders, K. M.; Koh, S. D.; Ward, S. M. Interstitial cells of cajal as pacemakers in the gastrointestinal tract. Annu. Rev. Physiol, 2006, 68, 307-343.
14. Borman, R. A.; Tilford, N. S.; Harmer, D. W.; Day, N.; Ellis, E. S.; Sheldrick, R. L.; Carey, J.; Coleman, R. A.; Baxter, G. S. 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br. J. Pharmacol., 2002, 135 (5), 1144-1151.
15. Jaffre, F.; Bonnin, P.; Callebert, J.; Debbabi, H.; Setola, V.; Doly, S.; Monassier, L.; Mettauer, B.; Blaxall, B. C.; Launay, J. M.; Maroteaux, L. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ. Res., 2009, 104 (1), 113-123.
16. Callebert, J.; Esteve, J. M.; Herve, P.; Peoc'h, K.; Tournois, C.; Drouet, L.; Launay, J. M.; Maroteaux, L. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice. J. Pharmacol. Exp. Ther., 2006, 317 (2), 724-731.
17. Schmuck, K.; Ullmer, C.; Engels, P.; Lubbert, H. Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS Lett., 1994, 342 (1), 85-90.
18. Barnes, N. M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology, 1999, 38 (8), 1083-1152.
19. Baxter, G. S. Novel discriminatory ligands for 5-HT2B receptors. Behav. Brain Res., 1996, 73 (1-2), 149-152.
20. Roger, V. L.; Go, A. S.; Lloyd-Jones, D. M.; Adams, R. J.; Berry, J. D.; Brown, T. M.; Carnethon, M. R.; Dai, S.; de, S. G.; Ford, E. S.; Fox, C. S.; Fullerton, H. J.; Gillespie, C.; Greenlund, K. J.; Hailpern, S. M.; Heit, J. A.; Ho, P. M.; Howard, V. J.; Kissela, B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Makuc, D. M.; Marcus, G. M.; Marelli, A.; Matchar, D. B.; McDermott, M. M.; Meigs, J. B.; Moy, C. S.; Mozaffarian, D.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Rosamond, W. D.; Sorlie, P. D.; Stafford, R. S.; Turan, T. N.; Turner, M. B.; Wong, N. D.; Wylie-Rosett, J. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation, 2011, 123 (4), e18-e209.
21. Connolly, H. M.; Crary, J. L.; McGoon, M. D.; Hensrud, D. D.; Edwards, B. S.; Edwards, W. D.; Schaff, H. V. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med., 1997, 337 (9), 581-588.
22. Rothman, R. B.; Baumann, M. H. Serotonergic drugs and valvular heart disease. Expert. Opin. Drug Saf, 2009, 8 (3), 317-329.
23. Cardiac Valvulopathy Associated with Exposure to Fenfluramine or Dexgenfluramine; Centers For Disease Control and Prevention: Nov 4, 97.
24. Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med., 2007, 356 (1), 6-9.
25. Setola, V.; Hufeisen, S. J.; Grande-Allen, K. J.; Vesely, I.; Glennon, R. A.; Blough, B.; Rothman, R. B.; Roth, B. L. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol., 2003, 63 (6), 1223-1229.
26. Pritchett, A. M.; Morrison, J. F.; Edwards, W. D.; Schaff, H. V.; Connolly, H. M.; Espinosa, R. E. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc., 2002, 77 (12), 1280-1286.
27. Donnelly, K. B. Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases. Toxicol. Pathol., 2008, 36 (2), 204-217.
28. Fitzgerald, L. W.; Burn, T. C.; Brown, B. S.; Patterson, J. P.; Corjay, M. H.; Valentine, P. A.; Sun, J. H.; Link, J. R.; Abbaszade, I.; Hollis, J. M.; Largent, B. L.; Hartig, P. R.; Hollis, G. F.; Meunier, P. C.; Robichaud, A. J.; Robertson, D. W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol., 2000, 57 (1), 75-81.
29. Rothman, R. B.; Baumann, M. H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther., 2002, 95 (1), 73-88.
30. Elangbam, C. S. Drug-induced valvulopathy: an update. Toxicol. Pathol., 2010, 38 (6), 837-848.
31. Jian, B.; Xu, J.; Connolly, J.; Savani, R. C.; Narula, N.; Liang, B.; Levy, R. J. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol., 2002, 161 (6), 2111-2121.
32. Poissonnet, G.; Parmentier, J. G.; Boutin, J. A.; Goldstein, S. The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications. Mini. Rev. Med. Chem., 2004, 4 (3), 325-330.
33. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged structures: applications in drug discovery. Comb. Chem. High Throughput. Screen., 2004, 7 (5), 473-494.
34. Sharif, N. A.; McLaughlin, M. A.; Kelly, C. R.; Katoli, P.; Drace, C.; Husain, S.; Crosson, C.; Toris, C.; Zhan, G. L.; Camras, C. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp. Eye Res., 2009, 88 (3), 386-397.
35. Schade, R.; Andersohn, F.; Suissa, S.; Haverkamp, W.; Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med., 2007, 356 (1), 29-38.
36. Glennon, R. A. Classical hallucinogens: an introductory overview. NIDA Res. Monogr, 1994, 146, 4-32.
37. Porter, R. H.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol., 1999, 128 (1), 13-20.
38. Nelson, D. L.; Lucaites, V. L.; Wainscott, D. B.; Glennon, R. A. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A,-HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 359 (1), 1-6.
39. Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.; Hufeisen, S. J.; Roth, B. L. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 2000, 102 (23), 2836-2841.
40. Stahura, F. L.; Bajorath, J. Virtual screening methods that complement HTS. Comb. Chem. High Throughput. Screen., 2004, 7 (4), 259-269.
41. Scheiber, J.; Jenkins, J. L.; Sukuru, S. C.; Bender, A.; Mikhailov, D.; Milik, M.; Azzaoui, K.; Whitebread, S.; Hamon, J.; Urban, L.; Glick, M.; Davies, J. W. Mapping adverse drug reactions in chemical space. J. Med. Chem., 2009, 52 (9), 3103-3107.
42. Hajjo, R.; Grulke, C. M.; Golbraikh, A.; Setola, V.; Huang, X. P.; Roth, B. L.; Tropsha, A. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. J. Med. Chem., 2010, 53 (21), 7573-7586.
43. Chekmarev, D. S.; Kholodovych, V.; Balakin, K. V.; Ivanenkov, Y.; Ekins, S.; Welsh, W. J. Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem. Res. Toxicol., 2008, 21 (6), 1304-1314.
44. Zauhar, R. J.; Moyna, G.; Tian, L.; Li, Z.; Welsh, W. J. Shape signatures: a new approach to computer-aided ligand-and receptorbased drug design. J. Med. Chem., 2003, 46 (26), 5674-5690.
45. Fourches, D.; Muratov, E.; Tropsha, A. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model., 2010, 50 (7), 1189-1204.
46. Tunkel, J.; Mayo, K.; Austin, C.; Hickerson, A.; Howard, P. Practical considerations on the use of predictive models for regulatory purposes. Environ. Sci. Technol., 2005, 39 (7), 2188-2199.
47. Jaworska, J.; Nikolova-Jeliazkova, N.; Aldenberg, T. QSAR applicabilty domain estimation by projection of the training set descriptor space: a review. Altern. Lab Anim, 2005, 33 (5), 445-459.
48. Bray, J. K.; Goddard, W. A. III The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. J. Mol. Graph. Model., 2008, 27 (1), 66-81.
49. Kim, S. K.; Li, Y.; Abrol, R.; Heo, J.; Goddard, W. A. III Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. J. Chem. Inf. Model., 2011, 51 (2), 420-433.
50. Martí-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. COMPARATIVE PROTEIN STRUCTURE MODELING OF GENES AND GENOMES. Annu. Rev. Biophys. Biomol. Struct., 2000(29), 291-325.
51. Bryson, K.; McGuffin, L. J.; Marsden, R. L.; Ward, J. J.; Sodhi, J. S.; Jones, D. T. Protein structure prediction servers at University College London. Nucleic Acids Res., 2005, 33 (Web Server issue), W36-W38.
52. Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M.; Siu, F. Y.; Liu, W.; Xu, H. E.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Structural Features for Functional Selectivity at Serotonin Receptors. Science, 2013.